Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese patients~* Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints~* Active plaque psoriasis at screening~* Inadequate response to at least one conventional synthetic DMARD~Exclusion Criteria:~* Non-plaque forms of psoriasis (with exception of nail psoriasis)~* History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence A (Type: EXPERIMENTAL): Tofacitinib 5 mg BID for 6 months
- Treatment Sequence B (Type: PLACEBO_COMPARATOR): Placebo for 3 months then tofacitinib 5 mg BID for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).